Is COMPUGEN LTD (CGEN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.5% / 30% | 52.7% / 30% | 0.1% / 30% | 12.52% / 5% | ✗ NOT HALAL |
| DJIM | 1.5% / 33% | 52.7% / 33% | 0.1% / 33% | 12.52% / 5% | ✗ NOT HALAL |
| MSCI | 2.5% / 33% | 89.8% / 33% | 0.2% / 33% | 12.52% / 5% | ✗ NOT HALAL |
| S&P | 1.5% / 33% | 52.7% / 33% | 0.1% / 33% | 12.52% / 5% | ✗ NOT HALAL |
| FTSE | 2.5% / 33% | 89.8% / 33% | 0.2% / 50% | 12.52% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 87.3% | |
| Operating Margin | 83.2% | |
| Net Margin | 48.6% | |
| Return on Equity (ROE) | 44.8% | |
| Return on Assets (ROA) | 14.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $32M |
| Free Cash Flow | $31M |
| Total Debt | $3M |
| Debt-to-Equity | 2.9 |
| Current Ratio | 6.6 |
| Total Assets | $157M |
Price & Trading
| Last Close | $2.06 |
| 50-Day MA | $1.97 |
| 200-Day MA | $1.69 |
| Avg Volume | 391K |
| Beta | 3.0 |
|
52-Week Range
$1.13
| |
About COMPUGEN LTD (CGEN)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is COMPUGEN LTD (CGEN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), COMPUGEN LTD is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is COMPUGEN LTD's debt ratio?
COMPUGEN LTD's debt ratio is 1.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.5%.
What are COMPUGEN LTD's key financial metrics?
COMPUGEN LTD has a market capitalization of $194M, trailing P/E ratio of 5.4, and revenue of $73M. The company maintains a gross margin of 87.3% and a net margin of 48.6%. Return on equity stands at 44.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.